Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 46,044 · FY2023 0 · FY2024 0 — 3-yr total 46,044
GM Pharmaceuticals LLC (GMP) is Georgia's largest pharmaceutical manufacturer, producing ~140 brands across 230+ dosage forms at its Ponichala (Tbilisi) plant — the largest pharma facility in the South Caucasus. Exports across the CIS with 600+ employees.
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 47,932 | 65,735 | 80,205 | 121,249 | 160,536 | 166,632 | 155,169 | 202,180 | +22.8% | |
| 39,985 | 43,716 | 52,661 | 49,725 | 50,296 | 50,360 | 53,404 | 60,873 | +6.2% | |
| TOTAL ASSETS | 87,917 | 109,451 | 132,866 | 170,974 | 210,832 | 216,992 | 208,573 | 263,052 | +16.9% |
| 9,664 | 5,633 | 6,594 | 13,884 | 16,654 | 32,882 | 19,057 | 15,021 | +6.5% | |
| 4,643 | 717 | 2,980 | 2,113 | 2,545 | 1,475 | 1,158 | 365 | -30.5% | |
| TOTAL LIABILITIES | 14,307 | 6,350 | 9,573 | 15,997 | 19,199 | 34,357 | 20,214 | 15,386 | +1.0% |
| 73,609 | 103,101 | 123,293 | 154,977 | 191,633 | 182,635 | 188,359 | 247,667 | +18.9% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 5,604 | 0 | 2,682 | 1,771 | 2,515 | 1,989 | 1,401 | 738 | -25.1% |
| Cash & Equivalents | 531 | 4,120 | 4,752 | 23,732 | 55,495 | 53,359 | 42,144 | 47,348 | +89.9% |
| Net Debt | 5,073 | 4,120 | 2,070 | 21,961 | 52,979 | 51,370 | 40,743 | 46,609 | nmf |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →